Premium
ADOPT: evidence for change?
Author(s) -
Burrill Peter
Publication year - 2007
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.109
Subject(s) - medicine , rosiglitazone , metformin , glibenclamide , type 2 diabetes , critical appraisal , gold standard (test) , intensive care medicine , alternative medicine , diabetes mellitus , endocrinology , pathology
Abstract A randomised controlled trial published in a peer‐reviewed journal is considered to be the ‘gold standard’ of information about the effectiveness of a treatment; however, critical appraisal of trials is required in order to judge the value and implications of the results. Here, the author presents an appraisal of the ADOPT study, which compared the efficacy of rosiglitazone, metformin and glibenclamide in the treatment of type 2 diabetes. Glycaemic durability of rosiglitazone, metformin, or glyburide monotherapy (the ADOPT study). N Engl J Med 2006;355:2427–43. Copyright © 2007 Wiley Interface Ltd